Cepheid (CPHD) Receives $40.43 Average Price Target from Analysts
Cepheid (NASDAQ:CPHD) has been assigned a consensus rating of “Hold” from the twenty-two brokerages that are covering the firm. Sixteen analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $41.18.
Several equities analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their target price on shares of Cepheid from $32.00 to $35.00 and gave the company a “neutral” rating in a research note on Friday, July 29th. BTIG Research lowered shares of Cepheid from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 7th. Zacks Investment Research raised shares of Cepheid from a “hold” rating to a “strong-buy” rating and set a $41.00 target price for the company in a research note on Monday, August 1st. TheStreet raised shares of Cepheid from a “sell” rating to a “hold” rating in a research note on Wednesday, September 28th. Finally, Barclays PLC lifted their target price on shares of Cepheid from $36.00 to $52.00 and gave the company an “equal weight” rating in a research note on Wednesday, September 7th.
In other news, VP Scott A. Campbell sold 746 shares of the business’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $36.71, for a total transaction of $27,385.66. Following the transaction, the vice president now owns 10,721 shares in the company, valued at approximately $393,567.91. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 4.16% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Societe Generale bought a new position in Cepheid during the second quarter valued at about $114,000. First Mercantile Trust Co. increased its position in Cepheid by 6.6% in the second quarter. First Mercantile Trust Co. now owns 4,020 shares of the company’s stock valued at $124,000 after buying an additional 250 shares during the last quarter. Globeflex Capital L P bought a new position in Cepheid during the second quarter valued at about $145,000. Advisor Group Inc. bought a new position in Cepheid during the second quarter valued at about $145,000. Finally, BlackRock Inc. increased its position in Cepheid by 77.0% in the first quarter. BlackRock Inc. now owns 4,814 shares of the company’s stock valued at $161,000 after buying an additional 2,094 shares during the last quarter. Institutional investors own 95.27% of the company’s stock.
Shares of Cepheid (NASDAQ:CPHD) opened at 52.66 on Friday. Cepheid has a 52 week low of $25.09 and a 52 week high of $53.91. The firm’s market capitalization is $3.84 billion. The stock’s 50 day moving average price is $49.52 and its 200 day moving average price is $36.23.
Cepheid (NASDAQ:CPHD) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.19. Cepheid had a negative net margin of 8.78% and a negative return on equity of 10.20%. The firm had revenue of $146 million for the quarter, compared to analysts’ expectations of $145.82 million. During the same period in the previous year, the company posted ($0.06) EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. On average, analysts predict that Cepheid will post $0.33 EPS for the current fiscal year.
Cepheid Company Profile
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Stock Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related stocks with our FREE daily email newsletter.